Yutiq now available for Chronic posterior segment Uveitis

EyePoint has announced the launch of Yutiq (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The product was approved by the Food and Drug Administration (FDA) in October 2018.

Yutiq is a sterile non-bioerodible intravitreal implant containing fluocinolone acetonide 0.18mg in a 36-month sustained-release drug delivery system. It is designed to release fluocinolone acetonide, a corticosteroid, at an initial rate of 0.25mcg/day.

YUTIQ™ (fluocinolone acetonide intravitreal implant) 0.18 mg is supplied with preloaded applicator with a 25-gauge needle for ophthalmic intravitreal injection administered in the physician's office for the treatment of chronic, non-infectious uveitis affecting the posterior segment of the eye. Adequate anaesthesia and a broad-spectrum microbicide should be given prior to the injection. Following the injection, patients should be monitored for change in intraocular pressure and for endophthalmitis.

"Yutiq is the first FDA-approved fluocinolone acetonide micro-insert to address this serious condition that is the third leading cause of blindness in the country," said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. "One micro-insert of Yutiq has the ability to deliver up to 3 years of fluocinolone acetonide, a commonly used steroid, with continuous dosing that avoids the peaks and valleys of local corticosteroids, the current standard of care."

“We are pleased to announce the availability of YUTIQ in the U.S., which is an advancement in the treatment of chronic, non-infectious posterior segment uveitis,” said Nancy Lurker, President and Chief Executive Officer of EyePoint Pharmaceuticals. “YUTIQ is the first FDA-approved fluocinolone acetonide micro-insert to address this serious condition that is the third leading cause of blindness in the country. One micro-insert of YUTIQ has the ability to deliver up to three years of fluocinolone acetonide, a commonly used steroid, with continuous dosing that avoids the peaks and valleys of local corticosteroids, the current standard of care. In clinical studies, YUTIQ significantly reduced the number of inflammatory uveitis eye flares, which can lead to blindness. We are proud to bring this innovative treatment to patients to address this high unmet need.”

A link to the full product label is available on the EyePoint Pharma website at: www.eyepointpharma.com/wp-content/uploads/2019/01/YUTIQ-USPI-20181120.pdf.